SOURCE: The Bedford Report

The Bedford Report

May 27, 2011 08:16 ET

China-Biotics and Sinovac Biotech Benefit From China's Biotech Revolution

The Bedford Report Provides Analyst Research on China-Biotics & Sinovac Biotech

NEW YORK, NY--(Marketwire - May 27, 2011) - With an improving quality of life that has resulted in larger paychecks and a more sophisticated understanding of health and wellness, China has been experiencing a massive biotech boom in recent years. The Bedford Report examines the outlook for companies in China's Healthcare Sector and provides research reports on China-Biotics, Inc. (NASDAQ: CHBT) and Sinovac Biotech Ltd. (NASDAQ: SVA). Access to the full company reports can be found at:

China's economic minister recently tapped biotech as one of seven key industries that the government intends to foster over the next 10 years. Zhou Zixue, chief economist of the Ministry of Industry and Information Technology, projects that biotech in China will grow at an annual rate of 24.1 percent between 2011 and 2015 before slowing down to a 21.3 percent growth rate in the following five years.

Sources told Reuters that in order to reach the goal China is considering investments of up to $1.5 trillion over the next five years in the industries of next-generation information technology, energy-saving, biotechnology and high-end equipment manufacturing.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Sinovac is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac reported a net loss of $2.1 million, or 5 cents per share, in the three months ended March 31 versus a net loss of $300,000, or a penny per share, a year ago.

China-Biotics engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Jinan Song, CEO and Chairman of China-Biotics, explains that while the company is focused on improving market share domestically, the company looks forward to "future growth opportunities in the international market." In March the company announced that it received a product sales order from a newly signed US customer -- its first order from the US.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information